Ruzica Kravljanac

Prof. Dr. Ruzica Kravljanac

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in European Journal of Paediatric Neurology
Verified
Journal Article
Closed access
Ruzica KravljanacRuzica Kravljanac
Ruzica Kravljanac
MDMilena Djuric
Milena Djuric
BJBorisav Jankovic
Borisav Jankovic
TPTatjana Pekmezovic
Tatjana Pekmezovic

1 March 2013 in Epilepsy Research
Verified
Journal Article
Closed access
Ruzica KravljanacRuzica Kravljanac
Ruzica Kravljanac
MDMilena Djuric
Milena Djuric
NJNebojsa Jovic
Nebojsa Jovic
MDMaja Djordjevic
Maja Djordjevic
DZDragan Zamurovic
Dragan Zamurovic
TPTatjana Pekmezovic
Tatjana Pekmezovic

4 March 2021 in Expert Review of Neurotherapeutics
Verified
Journal Article
Open access
MMMaria Mazurkiewicz-Bełdzińska
Maria Mazurkiewicz-Bełdzińska
MTMireia del Toro
Mireia del Toro
GHGöknur Haliloğlu
Göknur Haliloğlu
HHHidde Huidekoper
Hidde Huidekoper
Ruzica KravljanacRuzica Kravljanac
Ruzica Kravljanac
SAStéphane Auvin
Stéphane Auvin
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric neurodegenerative condition, which is usually fatal by mid-adolescence. Seizures are one of the most common early symptoms o...

14 July 2024 in Molecular Diagnosis & Therapy
Verified
Journal Article
Open access
PDF file
MAMarina Andjelkovic
Marina Andjelkovic
KKKristel Klaassen
Kristel Klaassen
ASAnita Skakic
Anita Skakic
IMIrena Marjanovic
Irena Marjanovic
Ruzica KravljanacRuzica Kravljanac
Ruzica Kravljanac
MSMaja Stojiljkovic
Maja Stojiljkovic
Background Childhood epilepsies are caused by heterogeneous underlying disorders where approximately 40% of the origins of epilepsy can be attributed to genetic factors. The application of next-generation sequencing (NGS) has revolutionized molecular diagnostics and has enabled the identification of disease-causing genes and variants in childhood epilepsies. The objective of this study was to use NGS to identify variants in patients with childhood epilepsy, to expand the variant spectrum and discover potential therapeutic targets. Methods In our study, 55 children with epilepsy of unknown etiology were analyzed by combining clinical-exome and whole-exome sequencing. Novel variants were characterized using various in silico algorithms for pathogenicity and structure prediction. Results The molecular genetic cause of epilepsy was identified in 28 patients and the overall diagnostic success rate was 50.9%. We identified variants in 22 different genes associated with epilepsy that correlate well with the described phenotype. SCN1A gene variants were found in five unrelated patients, while ALDH7A1 and KCNQ2 gene variants were found twice. In the other 19 genes, variants were found only in a single patient. This includes genes such as ASH1L, CSNK2B, RHOBTB2, and SLC13A5, which have only recently been associated with epilepsy. Almost half of diagnosed patients (46.4%) carried novel variants. Interestingly, we identified variants in ALDH7A1, KCNQ2, PNPO, SCN1A, and SCN2A resulting in gene-directed therapy decisions for 11 children from our study, including four children who all carried novel SCN1A genetic variants. Conclusions Described novel variants will contribute to a better understanding of the European genetic landscape, while insights into the genotype-phenotype correlation will contribute to a better understanding of childhood epilepsies worldwide. Given the expansion of molecular-based approaches, each newly identified genetic variant could become a potential therapeutic target.

1 December 2018 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
Ruzica KravljanacRuzica Kravljanac
Ruzica Kravljanac
NJNebojsa Jovic
Nebojsa Jovic
BTBiljana Vucetic Tadic
Biljana Vucetic Tadic
DKDjordje Kravljanac
Djordje Kravljanac
TPTatjana Pekmezovic
Tatjana Pekmezovic

4 August 2022 in Genes
Verified
Journal Article
Open access
PDF file
AKAna Kosac
Ana Kosac
JPJovan Pesovic
Jovan Pesovic
LRLana Radenkovic
Lana Radenkovic
MBMiloš Brkušanin
Miloš Brkušanin
NRNemanja Radovanovic
Nemanja Radovanovic
VRVedrana Milic Rasic
Vedrana Milic Rasic
Background: Clinical course variability in Duchenne muscular dystrophy (DMD) is partially explained by the mutation location in the DMD gene and variants in modifier genes. We assessed the effect of the SPP1, CD40, and LTBP4 genes and DMD mutation location on loss of ambulation (LoA). Methods: SNPs in SPP1-rs28357094, LTBP4-rs2303729, rs1131620, rs1051303, rs10880, and CD40-rs1883832 were genotyped, and their effect was assessed by survival and hierarchical cluster analysis. Results: Patients on glucocorticoid corticosteroid (GC) therapy experienced LoA one year later (p = 0.04). The modifying effect of SPP1 and CD40 variants, as well as LTBP4 haplotypes, was not observed using a log-rank test and multivariant Cox regression analysis. Cluster analysis revealed two subgroups with statistical trends in differences in age at LoA. Almost all patients in the cluster with later LoA had the protective IAAM LTBP4 haplotype and statistically significantly fewer CD40 genotypes with harmful T allele and “distal” DMD mutations. Conclusions: The modifying effect of SPP1, CD40, and LTBP4 was not replicated in Serbian patients, although our cohort was comparable in terms of its DMD mutation type distribution, SNP allele frequencies, and GC-positive effect with other European cohorts. Cluster analysis may be able to identify patient subgroups carrying a combination of the genetic variants that modify LoA.